Cardiometabolic Drugs Market Size & Share, by Drug Type (Weight Loss, Antidiabetics, Anticoagulants, Antiplatelet, Impaired Glucose Tolerance, Insulin Resistance, Hypertension, Dyslipidemia); Disease Type (Congestive Heart Failure, Hypertension, Diabetes, Obesity); Distribution Channel (Hospitals, Clinics, Retail Pharmacies, Online) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 4146
  • Published Date: Feb 24, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2023-2035

Cardiometabolic Drugs Market size is expected to surpass USD 72 Billion by the end of 2035, growing at a CAGR of 6% during the forecast period i.e., 2023-2035. In the year 2022, the industry size of cardiometabolic drugs was over USD 50 Billion.The major factor for market growth is the growing chronic diseases among the population owing to the adoption of unhealthy lifestyles, reduced physical activity, and increased consumption of packaged along with junk food. As cardiometabolic drugs are efficient in treating such diseases, their high prevalence is expected to drive market growth. As per the data released by the Centers for Disease Control and Prevention (CDC), six out of ten Americans are diagnosed with at least one chronic disease such as heart disease and stroke, cancer, and diabetes. 

The growth of the market can be attributed to factors, such as growing awareness toward the development of novel drugs to minimize the side effects, and escalating demand for drugs to treat cardiometabolic diseases. Some of the cardiometabolic diseases are non-alcoholic liver diseases, heart stroke or attack, insulin resistance, diabetes, and others. In addition, the prevalence of a large pool of a large number of patients owing to the changing lifestyle coupled with the escalation in the usage rate of biomarkers for diagnostic and risk assessment procedures is estimated to propel market growth in the upcoming years. Moreover, the rising focus on developing novel and advanced medicine to treat diseases with reduced side effects is considered to be another factor for the expansion of market size. One of the other factors that are expected to create a positive outlook for revenue generation is the increased fast-paced lifestyles, constant change in eating habits, and escalation in stress levels which is fostering the burden of lifestyles diseases such as diabetes, obesity, hypertension, and others which in turn is generating the need for cardiometabolic drugs during the analysis period.


Cardiometabolic Drugs Market
Get more information on this report: Request Free Sample PDF

Cardiometabolic Drugs Sector: Growth Drivers and Challenges

Growth Drivers

  • Growing Cases of Non-Communicable Diseases Across the World – With increasing urbanization, the number of non-communicable diseases across the world is increasing. For fast treatment process for these diseases and to enhance patient experience with reduced pain is expected to increase the demand for cardiometabolic drugs during the forecast period. Recent statistics revealed by the World Health Organization (WHO) stated that non-communicable diseases kill 41 million people each year which is equivalent to 74% of all deaths around the world.
  • Escalation in Prevalence of Cardiovascular Diseases – In the recent period, the prevalence of cardiovascular diseases such as coronary heart diseases, strokes, peripheral arterial diseases, and aortic diseases among the global population has surged. As a result, medical professionals have utilized cardiometabolic drugs for faster treatment processes. This trend is anticipated to bring lucrative growth opportunities for market growth in the next few years. As per the latest reports, cardiovascular diseases take almost 17 million lives every year across the globe.
  • The Surge in Lifestyle Disorders Including Cancer and Diabetes – For instance, recent statistics revealed that cancer is responsible for approximately 9 million deaths, chronic respiratory diseases for around 4 million deaths, and diabetes for about 2 million deaths every year worldwide.
  • Rising Approval of Medicines – The exponential growth in novel drug development and manufacturing process coupled with the rise in approval of medicines is anticipated to ease the commercialization process of cardiometabolic drugs in the next few years. For instance, in 2021, the Center for Drug Evaluation and Research (CDER) approved about 50 novel drugs to be sold out for consumption.
  • Upsurge in Research and Development Expenditure – Along with the rapid technological advancement, significant expenditure has been made in research and development activities to develop and manufacture high-quality, effective, and novel cardiometabolic drugs for treatment processes. Hence, creating a positive outlook for market expansion during the forecast period. According to the World Bank, global expenditure on research and development was calculated to be 2.63% of GDP in 2020 up from 2.2% in 2018.

Challenges

  • Rising Risks of Side Effects on the Human Body – Antidiabetics, anticoagulants, hypertension, dyslipidemia drugs, and other cardiometabolic drugs usually have side effects such as dyspepsia, vomiting, nausea, prolonged nosebleeds, passing of blood in urine, and others. Thus, the rising risks of these side effects are projected to slow down the adoption rate of cardiometabolic drugs in the long run which is subsequently expected to hamper the growth of the global cardiometabolic drugs market.
  • Frequent Changes in Guidelines and Security Policies
  • Increased Costs of Medicines

Cardiometabolic Drugs Market: Key Insights

Base Year

2022

Forecast Year

2023-2035

CAGR

~6%

Base Year Market Size (2022)

~ USD 50 Billion

Forecast Year Market Size (2035)

~ USD 72 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Cardiometabolic Drugs Segmentation

Disease Type (Congestive Heart Failure, Hypertension, Diabetes, Obesity)

The global cardiometabolic drugs market is segmented and analyzed for demand and supply by disease type into congestive heart failure, hypertension, diabetes, obesity, and others. Out of these, the diabetes segment is attributed to holding the largest share of the market during the forecast period. The major factor attributed to segment growth is the rising cases of dibetes among the people and increased diabetic inborn occurrences owing to the rising consumption of junk and adoption of an unhealthy lifestyle. Data released by International Diabetes Federation (IDF) in 2021 showed that about 537 million people aged between 20 to 79 have diabetes which is estimated to reach 783 million over the forecast period. Furthermore, instances of stress and hypertension as a result of engagement in a face-paced lifestyle are also propelling the growth of diabetes among the population which ultimately generates demand for cardiometabolic drugs for the treatment process. Also, as cardiometabolic drugs are highly effective for diabetic patients for diverse applications, such as insulin resistance, the growing diabetic population is projected to propel segment expansion and create remunerative opportunities in the global market. 

Distribution Channel (Hospitals, Clinics, Retail Pharmacies, Online)

The global cardiometabolic drugs market is also segmented and analyzed for demand and supply by distribution channel into hospitals, clinics, retail pharmacies, online, and others. Out of these five segments, the hospital segment is projected to hold the most significant share of the global market with a notable CAGR over the forecast period. Patients who are diagnosed with cardiovascular disorders and chronic diseases often visit hospitals for treatment, and it’s easier and more convenient for them to purchase the prescribed cardiometabolic drugs for treatment processes. Also, the increased inflow and outflow of patients in the hospitals is another factor for increased sales of cardiometabolic drugs through hospital settings. On the other hand, the online segment is also estimated to garner a noteworthy segment share by the end of the assessment period owing to the escalation of the number of online pharmacies selling cardiometabolic drugs amongst the population worldwide. Furthermore, the purchase of cardiometabolic drugs is very much convenient as one doesn’t have to physically visit a hospital, clinic, or pharmacy for the purchase. In addition to that, another growth factor for the expansion of segment size is the huge offers and rewards offered by various online pharmaceutical businesses to lure customers.

Our in-depth analysis of the global market includes the following segments:

            By Drug Type

  • Weight Loss
  • Antidiabetics
  • Anticoagulants
  • Antiplatelet
  • Impaired Glucose Tolerance
  • Insulin Resistance
  • Hypertension
  • Dyslipidemia
  • Others

          By Disease Type

  • Congestive Heart Failure
  • Hypertension
  • Diabetes
  • Obesity
  • Others

        By Distribution Channel

  • Hospitals
  • Clinics
  • Retail Pharmacies
  • Online
  • Others

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Cardiometabolic Drugs Industry - Regional Synopsis

North American Market Forecast

The North American cardiometabolic drugs market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2035 on the back of the presence of multiple key players in the market in the region and a higher prevalence of cardiovascular diseases and usage of cardiovascular devices. Centers for Disease Control and Prevention released data which revealed that in 2019, about 360,900 people died due to coronary heart disease, meanwhile, 1 person loses his life every 36 seconds due to heart disease in the United States. Furthermore, the North American region is projected to be the second-highest number of diabetes patients which in turn is projected to increase the sales of cardiometabolic drugs in the forecast period. According to the report from the National Institute of Diabetes and Digestive and Kidney Diseases, in 2020, 10.5% of the U.S. population had diabetes while an additional 8.2% of people were diagnosed with diabetes.

APAC Market Statistics

Furthermore, the global cardiometabolic drugs market is also projected to grow at a significant pace in the Asia-Pacific region during the forecast period. The growth of the market in the region can be attributed to similar factors, such as rising cases of cardiovascular diseases and a growing geriatric population with various types of diseases and disorders. Also, the rapid growth of the healthcare industry and rising investment in enhancing the healthcare system are other factors that are anticipated to create a positive outlook for generating significant revenue in the forecast period.

Research Nester
Cardiometabolic Drugs Market  Size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Cardiometabolic Drugs Landscape

top-features-companies
    • GSK plc
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Lupin Limited
    • Merck KGaA
    • Romark L.C.
    • Pfizer Inc.
    • Endo International plc
    • Bayer AG
    • Jazz Pharmaceuticals plc
    • Canopy Growth Corporation
    • InMed Pharmaceuticals Inc.

In the News

  • GSK plc acquires the approval from US Food and Drug Administration (FDA) for its Priorix, a vaccine for mumps, measles, and rubella in children 12 months old or above it.

  •  Lupin Limited to merge its path with Yabao Pharmaceutical Co., inc., based in China, to fulfill the escalating demand in the Chinese market for quality drugs with the pediatric formulation.

Author Credits:  Radhika Pawar


  • Report ID: 4146
  • Published Date: Feb 24, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing awareness toward the development of novel drugs and the growing demand for drugs to cure cardiometabolic diseases are the major factors driving the growth of the cardiometabolic drugs market.

The market is anticipated to attain a CAGR of ~6% over the forecast period, i.e., 2023 – 2035.

The possibility of significant side effects is estimated to hamper the market growth.

The market in the North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are GSK plc, Lupin Limited, Merck KGaA, Romark L.C., Pfizer Inc., Endo International plc, Bayer AG, Jazz Pharmaceuticals plc, Canopy Growth Corporation, InMed Pharmaceuticals Inc., and other key players.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue-generating capacity as well as the new products being launched into the market by the company.

The market is segmented by drug type, disease, distribution channel, and by region.

The hospital segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Cardiometabolic Drugs Market Report Scope
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying